Stephan Jackman
Chief Executive Officer chez ALZAMEND NEURO, INC.
Fortune : 3 033 $ au 31/03/2024
Profil
Stephan Jackman is currently the Chief Executive Officer & Director at Alzamend Neuro, Inc. He previously served as the Chief Operating Officer at Ennaid Therapeutics LLC from 2015 to 2017 and at Exit 9 Technologies, Inc. from 2017 to 2018.
Mr. Jackman received his undergraduate and graduate degrees from Stevens Institute of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ALZAMEND NEURO, INC.
0,04% | 24/08/2023 | 3 033 ( 0,04% ) | 3 033 $ | 31/03/2024 |
Postes actifs de Stephan Jackman
| Sociétés | Poste | Début |
|---|---|---|
| ALZAMEND NEURO, INC. | Chief Executive Officer | 20/11/2018 |
Anciens postes connus de Stephan Jackman
| Sociétés | Poste | Fin |
|---|---|---|
| Exit 9 Technologies, Inc. | Chief Operating Officer | 01/11/2018 |
Ennaid Therapeutics LLC
 Ennaid Therapeutics LLC BiotechnologyHealth Technology Ennaid Therapeutics LLC develops orally deliverable anti-viral peptide that treats and prevents Zika virus. The company was founded by Darnisha Grant Harrison in 2012 and is headquartered in Alpharetta, GA. | Chief Operating Officer | 01/10/2017 |
Formation de Stephan Jackman
| Stevens Institute of Technology | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALZAMEND NEURO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Ennaid Therapeutics LLC
Ennaid Therapeutics LLC BiotechnologyHealth Technology Ennaid Therapeutics LLC develops orally deliverable anti-viral peptide that treats and prevents Zika virus. The company was founded by Darnisha Grant Harrison in 2012 and is headquartered in Alpharetta, GA. | Health Technology |
| Exit 9 Technologies, Inc. |
